Intranasal immunization with dry powder vaccines
TF Bahamondez-Canas, Z Cui - European journal of pharmaceutics and …, 2018 - Elsevier
TF Bahamondez-Canas, Z Cui
European journal of pharmaceutics and biopharmaceutics, 2018•ElsevierVaccination represents a cost-effective weapon for disease prevention and has proven to
dramatically reduce the incidences of several diseases that once were responsible for
significant mortality and morbidity worldwide. The nasal cavity constitutes the initial stage of
the respiratory system and the first contact with inhaled pathogens. The intranasal (IN) route
for vaccine administration is an attractive alternative to injection, due to the ease of
administration as well as better patient compliance. Many published studies have …
dramatically reduce the incidences of several diseases that once were responsible for
significant mortality and morbidity worldwide. The nasal cavity constitutes the initial stage of
the respiratory system and the first contact with inhaled pathogens. The intranasal (IN) route
for vaccine administration is an attractive alternative to injection, due to the ease of
administration as well as better patient compliance. Many published studies have …
Abstract
Vaccination represents a cost-effective weapon for disease prevention and has proven to dramatically reduce the incidences of several diseases that once were responsible for significant mortality and morbidity worldwide. The nasal cavity constitutes the initial stage of the respiratory system and the first contact with inhaled pathogens. The intranasal (IN) route for vaccine administration is an attractive alternative to injection, due to the ease of administration as well as better patient compliance. Many published studies have demonstrated the safety and effectiveness of IN immunization with liquid vaccines. Currently, two liquid IN vaccines are available and both contain live attenuated influenza viruses. FluMist® was approved in 2003 in the United States, and Nasovac® H1N1 vaccine was approved in India in 2010. Preclinical studies showed that IN immunization with dry powder vaccines (DPVs) is feasible. Although there is not a commercially available DPV yet, DPVs have the inherent advantage of being relatively more stable than liquid vaccines. This review focuses on recent developments of DPVs as next-generation IN vaccines.
Elsevier
以上显示的是最相近的搜索结果。 查看全部搜索结果